Compression Garments Show Promise for Pain Relief in Hypermobility Disorders, Study Finds
Table of Contents
A new retrospective study suggests that compression garments (CGs) may offer meaningful pain relief for adults with hypermobility spectrum disorder (HSD) and hypermobile Ehlers-Danlos syndrome (hEDS), with 80% of patients experiencing positive effects. The findings, especially notable for including patients with HSD – a population often excluded from prior research – could reshape treatment approaches and potentially expand insurance coverage for these garments.
A Significant Reduction in Pain Reported
Researchers observed a pronounced reduction in pain among the majority of patients studied.This observation aligns with previous reports,including work by Bénistan et al., which documented decreases in pain at affected joints, neuropathic components, and joint instability. Notably, over half of the participants also reported a reduction in their use of pain medication, excluding acetaminophen, highlighting the potential for cost savings within healthcare systems.
Though, the study’s retrospective nature prevented a detailed analysis of specific medications used, dosage levels, and changes over time.
HSD vs. hEDS: Similar response too Compression
The study included 10 patients with HSD and 10 with hEDS. While those with hEDS showed a higher proportion of altered visceral proprioception, both groups responded to CGs to a similar extent. This is a novel observation, suggesting that individuals with HSD may benefit from compression therapy as much as those with hEDS.
Previously, research had largely focused exclusively on hEDS, making direct comparisons challenging. However, researchers note that both HSD and hEDS share common disease mechanisms and musculoskeletal and proprioceptive symptoms, supporting the idea of a shared sensory-motor dysfunction. This finding strengthens the case for including HSD patients in future prospective studies of compression therapy.
Reimbursement Challenges in France
Currently, in France, national health insurance covers compression garments for individuals with hEDS, but frequently denies coverage for those with HSD due to a lack of scientific evidence.The results of this study could potentially justify a reconsideration of these reimbursement criteria, expanding access to treatment for a broader patient population.
adherence and BMI: Key Predictors of Success
The study identified several factors associated with a positive treatment response. Consistent wear time was a strong predictor of success (p = 0.0013; r = 0.45), underscoring the importance of patient adherence. Conversely, intolerance to cgs was significantly linked to a lack of clinical benefit (p = 0.001).These findings suggest that sustained use of compression garments is crucial for achieving optimal outcomes, a hypothesis that requires confirmation in future research.
Interestingly, a higher Body Mass Index (BMI) was also associated with a more frequent clinical response.Researchers hypothesize that in individuals with greater body volume, CGs may achieve more uniform pressure distribution, enhancing joint stability, sensory stimulation, and proprioceptive feedback, ultimately contributing to pain reduction. While this concept is supported by biomechanical studies, further research is needed to explore the interplay between body composition and garment effectiveness.
The “On-Off” Effect: A Potential Indicator
Patients who reported an “on-off” effect – immediate symptom relief while wearing the garment, followed by a return of symptoms upon removal – were more likely to respond to CG-based treatment. Although not statistically significant, the trend suggests this phenomenon could serve as a clinical indicator of responsiveness, aligning with similar observations reported by Benistan et al. in hEDS patients.
Study Limitations and Future Directions
Researchers acknowledge several limitations, including the retrospective study design, a small sample size (n=20), and the lack of standardized instruments for measuring qol and fatigue. The use of a composite endpoint may also have overestimated effectiveness. Furthermore, the study acknowledges potential confounding factors, such as ongoing physiotherapy and medication changes.
future research should focus on identifying the ideal patient profile for CG therapy, including those with shorter durations of chronic pain, peripheral proprioceptive disturbances, and higher bmis. Prospective, controlled studies, particularly focusing on HSD, are needed, incorporating validated outcome measures and objective assessments of sensory function. Further examination is also warranted into optimal CG usage duration, the moast responsive anatomical sites, and potential synergistic effects with other therapies like braces and physiotherapy.
